How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Lea Bucher
Advertisement
Lea Bucher is Principal at Executive Insight.
Articles by Lea Bucher
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Sends Amended Acquisition Proposal to Metsera
2
Pharmaceutical Executive Daily: Kimberly-Clark’s $48.7 Billion Acquisition of Kenvue
3
Texas Files to Prevent Kenvue Dividend Payment
4
FDA Approves Kygevvi Becoming the First Treatment for Thymidine Kinase 2 Deficiency
5
